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Abstract
There is increasing interest in multi-allele vaccines to overcome strain-specificity against polymorphic vaccine targets such
as Apical Membrane Antigen 1 (AMA1). These have been shown to induce broad inhibitory antibodies in vitro and formed
the basis for the design of three Diversity-Covering (DiCo) proteins with similar immunological effects. The antibodies
produced are to epitopes that are shared between vaccine alleles and theoretically, increasing the number of component
AMA1 alleles is expected to broaden the antibody response. A plateau effect could however impose a limit on the number
of alleles needed to achieve the broadest specificity. Moreover, production cost and the vaccine formulation process would
limit the number of component alleles. In this paper, we compare rabbit antibody responses elicited with multi-allele
vaccines incorporating seven (three DiCos and four natural AMA1 alleles) and three (DiCo mix) antigens for gains in
broadened specificity. We also investigate the effect of three adjuvant platforms on antigen specificity and antibody
functionality. Our data confirms a broadened response after immunisation with DiCo mix in all three adjuvants. Higher
antibody titres were elicited with either CoVaccine HT
TM or Montanide ISA 51, resulting in similar in vitro inhibition (65–82%)
of five out of six culture-adapted P. falciparum strains. The antigen binding specificities of elicited antibodies were also
similar and independent of the adjuvant used or the number of vaccine component alleles. Thus neither the four extra
antigens nor adjuvant had any observable benefits with respect to specificity broadening, although adjuvant choice
influenced the absolute antibody levels and thus the extent of parasite inhibition. Our data confirms the feasibility and
potential of multi-allele PfAMA1 formulations, and highlights the need for adjuvants with improved antibody potentiation
properties for AMA1-based vaccines.
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Introduction
Malaria is a disease caused by the apicomplexan parasite
Plasmodium and remains a global scourge despite recent coordi-
nated efforts at control and prevention in endemic areas. The
development of an effective malaria vaccine has become ever more
urgent in the face of increasing parasite/vector resistance to
currently available drugs/insecticides for disease treatment and
vector control [1–3]. Subunit vaccine development requires the
identification of immunogenic targets from the wide array of
antigens expressed by the parasite. A number of antigens
expressed by Plasmodium falciparum, the parasite mostly responsible
for severe forms of malaria, are currently at various stages of pre-
clinical and clinical testing [4–6] with apical membrane antigen 1
(AMA1) being an important candidate. The vaccine properties
and potential of AMA1 have recently been reviewed [7].
Despite the current global interest in AMA1 as a vaccine
component, its potential is limited by allelic polymorphism
resulting from single amino acid substitutions in an estimated
16% of amino acids (100 out of 622 positions in 1294 sequences
accessed from GenBank) within the AMA1 molecule (Remarque,
unpublished data). Polymorphism is generally an immune evasion
strategy of the parasite that renders a fully functional immune
response against one parasite strain less effective against strains
expressing other allele variants, and this has been extensively
demonstrated for AMA1 in murine models [8–10] as well as in
clinical trials in malaria-naive populations [11]. This suggests that
the immune response to AMA1, believed to be mainly antibody-
mediated, is to both strain-specific and conserved epitopes
[12–14]. We have previously shown that for any PfAMA1 allele,
the cross-strain anti-PfAMA1 antibody fraction inhibits the
homologous parasite strain in vitro to a similar extent as the total
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tested at the same concentration [15]. On this premise, a
universally effective PfAMA1 vaccine should have two basic
features; i) be able to induce functional responses to antibody
epitopes that are common to, or conserved in the widest diversity
of parasite strains possible, and ii) be such that strain-specific
epitopes on the component alleles are diluted out or eliminated
from the epitope repertoire. Attempts at achieving such responses
have been made through immunisation with recombinant vaccines
incorporating a number of PfAMA1 alleles [15–17], and have
been the basis for the in silico design of three Diversity-Covering
(DiCo) PfAMA1-based proteins with similar immunological effects
when mixed in a vaccine formulation [18]. The three DiCo
proteins, incorporating 80–97% of AMA1 amino acid diversity
found naturally at the time of design, are distinctly different from
one another and are together expected to elicit functional cross-
strain antibodies. Initial functional assays with protein A-purified
rabbit antibodies (6 mg/ml) against DiCo mix in Montanide ISA
51 showed an average in vitro inhibition of 70% against the highly
diverse FVO, HB3 and 3D7 parasite strains [18].
It seems reasonable to assume that increasing the number of
different PfAMA1 alleles included in such a multi-allele vaccine
would further broaden the specificity of the expected anti-PfAMA1
antibody response. This idea raises the question of how many
alleles would be necessary to achieve the broadest possible
functional antibody response. It should also be noted that the
number of alleles that can be included in such a vaccine would be
limited by the cost of producing many different antigens prior to
mixing, and the potential inherent difficulties with quality
assurance/control required for vaccine formulation. Another level
of complexity would be the appropriate adjuvant system for
vaccine formulation. Adjuvants are known to modulate the
specificity of antibodies elicited against some parasite antigens
[19,20].
In the present study, we further examine the broadened
antibody response after immunisation of rabbits with a mixture
of the three DiCo proteins by competition ELISA and in vitro
growth inhibition assays (GIAs) with six distinct P. falciparum
parasite strains. We compare this response with that induced by a
similar immunisation with a mixture of seven antigens (the three
DiCo proteins and natural AMA1 alleles from FVO, HB3, 3D7
and CAMP strains of P. falciparum) for gains in broadened
specificity. We also assess the effect of the choice of adjuvant on
the antigen specificities of antibodies elicited against the DiCo mix
vaccine.
Our data suggests a practical limit to the number of PfAMA1
alleles that need to be incorporated in a multi-allele vaccine to
achieve broad specificity, and shows no adjuvant effect on antigen
binding specificity of the elicited antibodies. It also highlights a
potentially important role for cross-reactive antibodies in naturally
acquired immunity to malaria, and the need for new adjuvants
with improved antibody potentiation properties and safety for use
in PfAMA1-based subunit vaccine development.
Methods
Ethics Statement
All animals used in this study were handled in strict accordance
with good animal practices within the respective jurisdictions
(German and European Union guidelines for BioGenes GmbH,
Berlin, and the Belgian national animal welfare regulations for
Eurogentec SA, Seraing). Rabbit immunisation work at BioGenes
was under approval from NIH/OLAW (ID number #A5755-01)
and immunisations at Eurogentec had approval from the ethics
committee of the Centre d’Economie Rurale (CER Groupe,
Marloie, Belgium).
Protein Production, Adjuvants and Rabbit Immunisations
The full ectodomain of the AMA1 allelic forms from P.
falciparum strains FVO, HB3, 3D7 and CAMP, as well as the in
silico-designed DiCo 1, DiCo 2 and DiCo 3 antigens were
expressed as recombinant proteins in Pichia pastoris by a similar
methodology as described elsewhere [21]. Groups of rabbits were
immunised with PfAMA1 multi-allele formulations in three
different adjuvants. CoVaccine HT
TM, an enhancer of both
humoral and cellular immune responses, is a novel proprietary
vaccine adjuvant from Protherics Medicines Development Limit-
ed, a BTG Company (London, UK). It is a squalene-based oil-in-
water adjuvant that has a sucrose fatty acid sulphate ester (SFASE)
[22]. Montanide ISA 51 is a water-in-oil emulsion developed by
SEPPIC (Paris, France), containing the naturally metabolizable oil
Drakeol 6 VR and mannide mono-oleate as emulsifier, and the
adjuvant promotes antibody formation and significant cytotoxic T-
cell activity [23,24]. Montanide IMS 4112 VG PR, (one of the
Montanide IMS group of adjuvants from SEPPIC), is a water-
dispersible composition containing (undisclosed) immuno-stimula-
tory organic compounds and excipient [25].
The first group of rabbits (Gp 1, n=9) was immunised with a
mixture of 7 antigens (DiCo 1, DiCo 2, DiCo 3, and PfAMA1
allelic antigens from FVO, HB3, 3D7 and CAMP parasite strains,
,7 mg of each antigen, 50 mg total antigen per dose) in CoVaccine
HT
TM. The second group (Gp 2, n=8) was immunised with a
mixture of 3 antigens (,17 mg each of DiCo 1, DiCo 2 and DiCo
3, here referred to as DiCo mix; 50 mg in total) in CoVaccine
HT
TM. The third group of rabbits (Gp 3, n=8) was immunised
with DiCo mix (,17 mg of each DiCo protein, 50 mg in total) in
Montanide IMS, and the fourth group (Gp 4, n=5) with DiCo
mix (10 mg of each DiCo protein, 30 mg in total) in Montanide ISA
51. All immunisations were done intramuscularly with 3 full
human doses (500 ml/dose) of vaccine on days 0, 28 and 56, and
exsanguination for all groups was on day 70. Vaccine formulation
in all cases was according to the adjuvant manufacturers’
specifications. For CoVaccine HT
TM, formulation involved
mixing 300 ml of antigen at 200 mg/ml with 300 ml of CoVaccine
HT
TM with an SFASE concentration of 40 mg/ml. One 500-ml
dose of the resulting formulation therefore contained 50 mg
antigen and 10 mg SFASE. Montanide IMS formulation also
involved mixing 300 ml of antigen with 300 ml of adjuvant such
that 500 ml of the resulting mixture contained 50 mg of antigen.
Formulation with Montanide ISA 51 was in a 50/50 (w/w) ratio of
antigen to adjuvant; 276 ml of antigen at 130 mg/ml was mixed
with 324 ml of adjuvant and the mixture was emulsified by 20
passages through a 22-gauge syringe-coupling piece prior to
injection with 500 ml.
Rabbits in the first three immunisation groups were housed at
BioGenes GmbH (Berlin, Germany), while the last group (Gp 4)
was housed at Eurogentec SA (Seraing, Belgium). The second and
third group immunisations (Gp 2 and Gp 3) were done
simultaneously in the same experiment at BioGenes, while the
first and fourth (Gp 1 and Gp 4) were done in separate
experiments. Final bleed sera from the four different immunisation
groups were used in the assays described here.
Antibody Purification
Antibodies from all groups were purified on Protein G
sepharose (GE Healthcare, Etten-Leur, The Netherlands) col-
umns. Binding and elution buffers (Pierce, Rockford, IL) were used
according to manufacturer’s protocols. After elution, antibody
PfAMA1 Multi-Allele Vaccine Formulation
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e15391eluates were filtered (0.22 mm), concentrated and exchanged into
RPMI 1640 using pre-sterilized AmicronUltra-15 tubes (30-kDa
cutoff; Millipore, Ireland). The concentration of each antibody
fraction was subsequently determined with a Nanodrop ND1000
spectrophotometer using the IgG molar extinction coefficient
(Nanodrop Technologies, Wilmington, DE) and stored at 220uC
until use.
ELISA
Competition ELISA was performed as previously described
[15]. Briefly, 96-well flat bottom Microlon titre plates (Greiner,
Alphen a/d Rijn, The Netherlands) were coated with 1 mg/ml
(100 ml/well) of the relevant antigen (DiCo 1, DiCo 2, DiCo 3,
FVO AMA1, HB3 AMA1, CAMP AMA1 or 3D7 AMA1) at 4uC
overnight. After blocking with 200 ml/well of 3% BSA in PBS-T,
60 mg/ml of each of six competitor/soluble antigens (AMA1 from
strains FVO, HB3, 3D7 or CAMP, a mixture of the 4 AMA1
alleles designated NM, and DiCo mix designated DM) were
titrated 3-fold over 9 duplicate wells at a 50 ml/well final volume.
Fifty microlitres/well of a fixed dilution (two arbitrary units or
2 AU) of rabbit IgGs (titre pre-determined using the relevant
capture antigen) was then added to the titrated competitor
antigens and co-incubated for 2 h. A pool of sera from rabbits
immunised with a mixture of 3 PfAMA1 alleles (FVO, HB3, 3D7
strains), titrated 2-fold from 1:100,000, was used as standard
calibrator on all plates. After sample incubation, plates were
developed with 100 ml/well of 1:1250-diluted goat anti-rabbit
IgG/alkaline phosphatase conjugate (Pierce, Rockford, IL).
Colour development was with 100 ml/well of p-nitrophenyl
phosphate (pNPP; Fluka, Poole, UK) for 30 min. and the optical
density (OD) at 405 nm determined.
Measured ODs were converted to arbitrary units (AUs) by the
standard curve included on each plate and expressed as a
percentage of AU values from wells without competitor antigen.
Residual binding (%) at the highest competitor antigen con-
centration was estimated from AU values based on a least
squares approximation from the following four-parameter logistic
function;
Y~
100{Y min ðÞ
1ze Xmid{X ðÞ sc zY min
where Y is the predicted % residual binding, Ymin is the maximal
depletion at infinite soluble antigen concentration (minimum
value), X is the soluble antigen concentration (log scale), Xmid is
the soluble antigen concentration (log scale) at which 50%
antibody depletion is achieved (midpoint between the maximum
and minimum depletion values), and sc is the slope of the curve.
Percent antibody depletion for any competitor/soluble antigen is
therefore the difference between 100% (binding in the absence of
soluble antigen) and residual binding at the highest competitor
antigen concentration of 30 mg/ml.
Parasite Cultures and Growth Inhibition Assays
Protein G-purified IgG fractions were tested for in vitro activity
in parasite growth inhibition assays (GIAs). All IgGs were tested in
triplicate on FCR3 (one amino acid difference in the pro-domain
from the FVO strain, with ama1 GenBank accession no. M34553),
NF54 (parent strain of the 3D7 clone with ama1 GenBank
accession no. U65407), HB3 (accession no. U33277), L32
(accession no. EF221749), 7G8 (accession no. M34555) and
CAMP (accession no. M34552) parasite strains at a 2-fold serial
dilution from 6 mg/ml in 96-well half area cell culture plates
(Greiner, Alphen a/d Rijn, The Netherlands). Parasites were
cultured under standard conditions (an atmosphere of 5% CO2,
5% O2, and 90% N2,3 7 uC), and the PfAMA1 antigens expressed
by all parasite strains were verified by PCR and restriction
fragment length analysis. Parasite cultures were mycoplasma-free
and synchronized with 0.3 M Alanine, 10 mM Hepes pH 7.5
before use in assays. Late trophozoite/early schizont stages at a
parasitaemia of 0.360.1% and 2% final haematocrit were used in
all assays. The final culture volume was 50 ml/well and parasites
were incubated for 42–46 h. Parasite growth was assessed by
measuring parasite lactate dehydrogenase levels and plates were
read at 655 nm after 30 min of development. Parasite growth
inhibition was expressed as;
% inhibition~100{
A655Sample{A655RBC ðÞ
A655SZ{A655RBC ðÞ
|100
where A655Sample is the OD655 for any test sample well, A655SZ is
the average OD655 of schizont control wells included on each plate
and A655RBC is the average OD655 of RBC control wells. The data
is presented as the arithmetic mean % inhibition from each sample
triplicate.
Statistical Analyses
Residual antibody binding (Ymin) for each competitor antigen in
competition ELISA was estimated by a 4-parameter logistic fit
with least squares approximation using the R statistical package (R
Development Core Team, 2009, version 2.10.1). The mean %
depletion (100-Ymin) and 95% confidence intervals of a competitor
antigen on one capture antigen were calculated and compared
with mean values of the same competitor antigen on other capture
antigens within the same immunisation group, or with mean
values obtained for the same competitor antigen in other
immunisation groups.
ELISA antibody titres on seven different capture antigens are
presented as dotplots superposed with boxplots indicating the
median as well as the lower and upper quartiles for each
immunisation group. GIA data is presented as the mean %
growth inhibition 6 standard error of mean per immunisation
group against each of the six parasite strains tested. Associations
between antibody titre and GIA activity for four parasite strains
with matching ELISA data were estimated with a four-parameter
logistic fit.
The original Gp 1 study involved 98 rabbits immunised with the
seven-antigen mixture in CoVaccine HT
TM. ELISA was per-
formed on a random sample of 9 out of the 98 available. Since
small volumes (,100 mL) of the individual rabbit sera were
available, only a single antibody sample, representing a pool of
IgGs from the 98 rabbits, was available for in vitro growth
inhibition assay. The growth inhibitory capacity of this single
sample against three parasite strains (FCR3, HB3, NF54) was
therefore compared directly with that of IgGs purified from a pool
of sera from all 8 rabbits immunised with DiCo mix in CoVaccine
HT
TM (Gp 2).
All plots were prepared with the R statistical package.
Results
Three-Antigen and Seven-Antigen Immunisations Induce
Antibodies with Similar Specificity Profiles
Specificity profiles of antibodies from rabbit immunisations with
the three-antigen (DiCo mix, Gp 2) and seven-antigen (DiCo mix
PfAMA1 Multi-Allele Vaccine Formulation
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falciparum, Gp 1) vaccines, both formulated in CoVaccine HT
TM,
were determined by a standardized competition ELISA with the
three DiCo proteins used separately as capture antigens. Initial
titrations with the separate DiCos as capture antigens showed that
antibody titres were higher (1.4–1.7 times) in the three-antigen
immunisation group (Gp 2) compared to the seven-antigen
immunisation group (Gp 1), and the differences were statistically
significant when DiCo1 and DiCo 2 were used as capture antigens
(Figure 1).
In competition ELISA, antibodies from the three and seven-
antigen immunisation regimens were co-incubated with four
natural PfAMA1 alleles (from 3D7, HB3, FVO and CAMP
parasite strains) and two different antigen mixtures (DiCo mix or
DM, and a mixture of the four natural PfAMA1 alleles, designated
NM) in coated and blocked plates. Antibody depletion by all 6
competitor antigens/mixtures was fairly consistent for all rabbits
within the same immunisation group when assays were done on
DiCo 1, DiCo 2 and DiCo 3-coated plates, respectively. Statistical
comparison of all rabbit antibodies from the three-antigen (Gp 2,
n=8) and seven-antigen (Gp 1, n=9) immunisation groups, both
formulated in Co-Vaccine HT, showed no significant difference in
mean % antibody depletion by all six competitor antigens/
mixtures (Table 1, Gps 1 & 2). For both vaccines, antibody
depletion by the competitor antigen mixtures (DM and NM) was
between 91% and 99% on all three DiCo capture antigens as was
expected (Table 1). Of the four natural PfAMA1 competitor
antigens, HB3 AMA1 depleted the most antibodies (87–95%) on
all the DiCo capture antigens, whilst 3D7 AMA1 depleted the least
(67–82%) (Table 1, Gps 1 & 2). The mean % antibody depletion
amongst competitor antigens varied most on DiCo 2-coated plates
compared to DiCo 1- and DiCo 3-coated plates. Mean %
antibody depletion was least for 3D7 AMA1 (,68%) on DiCo 2-
coated plates, irrespective of whether the antibodies were raised
with the three- or seven-antigen vaccines. By contrast, mean %
antibody depletion was greatest for FVO AMA1 competitor
Figure 1. Levels of anti-AMA1 antibody elicited with the four multi-allele vaccine formulations in rabbits. Gp 1 rabbits were immunised
with seven AMA1 antigens (DiCo mix and AMA1 from FVO, HB3, 3D7 and CAMP parasite strains) in CoVaccine HT
TM, and the other groups were
immunised with DiCo mix in CoVaccine HT
TM (Gp 2), Montanide IMS (Gp 3) and Montanide ISA 51 (Gp 4) respectively. Antibody titres were
determined by a standardized ELISA with DiCo 1, DiCo 2, DiCo 3, FVO, HB3, 3D7 and CAMP AMA1-coated plates. Data is presented on a Log2 scale as
dotplots with a boxplot superpose indicating the lower and upper quartiles as well as the median per immunisation group. Within the same
immunisation group, plotting symbols represent the antibody titre of individual rabbits on all coating/capture antigens.
doi:10.1371/journal.pone.0015391.g001
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three- and seven-antigen immunisations) and HB3 AMA1 (94.4%
and 94.0%, respectively) on DiCo 2-coated plates. 3D7 AMA1 as
a competitor antigen depleted most antibodies from both
immunisation groups (80.6% and 82.1% respectively for antibod-
ies raised in the three- and seven-antigen immunisations) on DiCo
3-coated plates (Table 1, Gps 1 & 2).
The 9 antibody samples from the seven-antigen immunisation
in CoVaccine HT
TM were randomly selected from a total of 98
such rabbits, and a pool of antibodies from all 98 rabbits was
subsequently tested in GIA. The ELISA antibody depletion
pattern of this IgG pool was shown to be similar to that of the
individual antibody samples (data not shown).
Differences in % antibody depletion amongst the four allelic
PfAMA1 competitor antigens may be related to the DiCo protein
coverage of polymorphism found in natural alleles. Alignments of
DiCo protein amino acid sequences with those of the four natural
alleles (Figure 2) reveal that apart from position K376 which was
mutated in the three DiCo proteins to avoid protein cleavage,
there are five other positions in 3D7 AMA1 that are not present in
any of the DiCo proteins. CAMP AMA1 sequences have two
uncovered positions, HB3 AMA1 has three and FVO AMA1 has
all amino acid residues represented at least once in the three DiCo
proteins.
The Majority of Antibodies Raised in Three-Antigen and
Seven-Antigen Immunisations Recognise Shared
Epitopes in Natural PfAMA1 Alleles
In order to further test the hypothesis that multi-allele vaccines
induce high proportions of antibodies to epitopes that are shared by
the vaccine component alleles, the specificities of antibodies elicited
by all four vaccine formulations to four different PfAMA1 alleles
were assessed by competition ELISA. Antibody titres were initially
determined by a standard ELISA on plates coated with PfAMA1
Table 1. Mean % antibody depletion from DiCo 1, 2 and 3-coated plates.
Capture antigen Competitor antigen Gp 1 (7Ag/HT) n=9 Gp 2 (3Ag/HT) n=8 Gp 3 (3Ag/IMS) n=8 Gp 4 (3Ag/ISA 51) n=5
DiCo 1 FVO 84.7
(81.6–87.8)
83.0
(79.5–86.6)
77.0
(71.9–82.0)
77.4
(73.0–81.8)
HB3 93.9
(91.7–96.1)
90.1
(88.5–91.6)
90.7
(87.9–93.6)
83.4
(76.7–90.1)
DM 96.1
(93.9–98.3)
98.6
(98.2–99.1)
97.2
(95.9–98.4)
91.9
(88.3–95.5)
CAMP 87.6
(84.2–90.9)
86.3
(84.5–88.0)
78.3
(74.5–82.1)
77.4
(71.4–83.5)
3D7 75.2
(72.2–78.2)
76.9
(73.1–80.8)
69.3
(65.0–73.6)
61.4
(54.9–68.0)
NM 97.6
(96.1–99.0)
92.4
(91.3–93.4)
92.1
(90.8–93.5)
88.2
(85.8–90.6)
DiCo 2 FVO 90.0
(87.2–92.8)
86.4
(84.2–88.6)
84.8
(79.4–90.2)
83.6
(81.2–86.1)
HB3 94.0
(91.8–96.2)
94.4
(91.1–97.8)
97.1
(94.8–99.4)
83.7
(71.6–95.7)
DM 96.1
(93.9–98.4)
97.6
(96.4–98.9)
98.1
(96.6–99.6)
92.9
(90.4–95.5)
CAMP 83.0
(79.6–86.4)
83.5
(80.1–87.0)
77.9
(75.3–80.5)
77.3
(76.1–78.6)
3D7 67.6
(63.3–71.9)
68.3
(65.9–70.6)
63.6
(58.7–68.5)
56.6
(48.3–64.9)
NM 95.0
(93.7–96.4)
92.9
(91.2–94.7)
95.0
(92.2–97.8)
88.9
(85.5–92.3)
DiCo 3 FVO 81.2
(77.7–84.6)
81.9
(78.2–85.6)
72.8
(66.9–78.7)
74.1
(66.8–81.4)
HB3 91.9
(89.6–94.3)
87.1
(85.2–88.9)
85.1
(82.5–87.7)
80.9
(74.8–87.0)
DM 97.3
(92.2–102.2)
97.8
(96.4–99.3)
96.8
(95.4–98.2)
91.0
(89.1–92.9)
CAMP 80.2
(77.0–83.3)
80.8
(76.7–84.9)
66.3
(59.7–73.0)
67.8
(62.5–73.1)
3D7 82.1
(78.6–85.6)
80.6
(77.9–83.2)
66.5
(61.4–71.7)
57.8
(47.9–67.6)
NM 94.2
(93.1–95.4)
91.4
(89.0–93.7)
86.5
(83.6–89.4)
84.0
(77.6–90.4)
Antibody depletion after competition ELISA, values reported as mean % depletion (95%CI).
7Ag – vaccine containing DiCo mix + four AMA1 alleles from FVO, HB3, 3D7 and CAMP parasite strains.
3Ag – vaccine containing DiCo mix.
NM &DM – competitor antigen mixtures comprising natural AMA1 alleles (FVO, HB3, 3D7, CAMP) and DiCo mix, respectively.
doi:10.1371/journal.pone.0015391.t001
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titres were comparable to those obtained when the same antibodies
were titrated on the immunising DiCo antigens (Figure 1). In our
hands, rabbit immunisations with antigen from concentrations of
30–100 mg/ml have usually yielded similar results, hence the
differencesintheantigendosebetweenthefirstthreegroupsandthe
DiCo mix/Montanide ISA 51 group (Gp 4) may not result in
different titres. ThefourPfAMA1 alleles(fromFVO, HB3,3D7and
CAMP parasite strains) were used as competitor antigens in
subsequent competition ELISA on plates coated with FVO and
3D7 AMA1 antigens respectively. In assays performed with FVO
AMA1-coated plates, antibodies from all four immunisation groups
showed the greatest depletion with the homologous FVO AMA1
(94–98%) and HB3 AMA1 (94–97%) as expected (Table 2). CAMP
AMA1 and 3D7 AMA1 depleted 78–84% and 67–82%, respec-
tively. Likewise, assays performed with 3D7 AMA1-coated plates
using the same rabbit antibodies resulted in 92–98% depletion by
3D7 AMA1, 85–86.5% depletion by CAMP AMA1, 88–90.5%
depletion by HB3 AMA1 and 81–84% depletion by FVO AMA1
(Table 2). Between groups, antibody depletion by an individual
competitor antigen was similar on the same capture antigen, and
irrespective of the number of immunising antigens (Table 2, Gps 1
& 2) or the adjuvant used in vaccine formulation (Table 2, Gps 2, 3
& 4). On average, for all immunisation groups, the extent of
recognition of FVO-binding antibodies by 3D7 AMA1 competitor
antigen was about 8.8% less than the recognition of 3D7 AMA1-
binding antibodies by FVO AMA1 competitor antigen. These
observations indicate that though the majority of antibodies
recognise shared epitopes in the four natural PfAMA1 alleles, a
fraction of antibodies are still strain-specific. This may be explained
by assuming that some antigen-specific epitopes on any of the three
DiCo proteins is/are not present on the PfAMA1 alleles of interest.
Antibodies elicited against such epitopes only recognize the
PfAMA1 allele(s) that have these epitopes and will not bind to
alleles without these strain-specific epitopes. Additionally, local
distortions of the protein structure resulting from changes in amino
acids that are in close proximity to, or within these epitopes may
mean antibodies will have lower binding avidity/affinity for these
epitopes. This may result in a continuum of binding specificities,
such that some antibodies will have high avidity for epitopes on
some PfAMA1 alleles and lower avidity for corresponding, albeit
alteredepitopesonotheralleles.Withthe exceptionofFVOAMA1,
Figure 2. Alignment of the protein sequences (aa25-545) of PfAMA1 antigens used in this study. DiCo proteins were used to immunise
rabbits and as capture antigens in ELISA. Natural allele AMA1 proteins were used to immunize rabbits, and as capture and competitor antigens in
(competition) ELISAs. All proteins were produced in Pichia pastoris and are devoid of N-glycosylation sites. These have been replaced with amino acid
residues (indicated in red) that occur in AMA1 sequences from other malarial species (N162Q, T288V, S373D, N422D, S423K, N499Q). Residue 162 is
unique as it is also a polymorphic residue. Additionally, all sequences contain a point mutation at position 376 (K to R, indicated in orange). This was
necessary to prevent protein cleavage by P. pastoris proteases.
doi:10.1371/journal.pone.0015391.g002
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not present in any of the three DiCo proteins (Figure 2). Epitopes
that include these polymorphic amino acids are therefore prime
candidatesthat may explain the remnant strain-specificity observed.
The Choice of Adjuvant Determines the Quantity but not
the Antigen Specificity of Elicited Antibodies
In order to assess the effect of adjuvant on the specificity of
elicited responses, rabbit antibodies raised against DiCo mix in
Co-Vaccine HT (Gp 2, n=8) were compared with those raised in
separate immunisations with DiCo mix in Montanide IMS (Gp 3,
n=8) and Montanide ISA 51 (Gp 4, n=5) as adjuvants. Antibody
titres were dependent on the vaccine adjuvant when titrated in
DiCo 1-, DiCo 2- or DiCo 3-coated plates. Antibody titres were
generally comparable in the immunisation groups with Co-
Vaccine HT and Montanide ISA 51, whilst titres were
comparatively lower in the Montanide IMS group (Figure 1,
Gps 2, 3 & 4)). Additionally, depletion patterns in competition
ELISA showed a general, albeit insignificant trend of higher %
depletions of antibodies against DiCo mix in CoVaccine HT
TM
(Gp 2) by all competitor antigens/mixtures, with 3D7 and CAMP
AMA1 competitor antigens showing only borderline significance
in some instances (Table 1, Gps 2, 3 and 4). Depletion of
antibodies from the two Montanide immunisation groups was also
generally comparable except for the two competitor antigen
mixtures DM and NM. Thus though the choice of an adjuvant for
immunisation affected the physiological levels of anti-DiCo mix
antibodies in rabbits, the current data suggests that the adjuvant
effect on epitope presentation to B cells, and by extension on the
antibody specificity, may only be marginal. This may however be
applicable only to the three adjuvants used in this study.
In Vitro Functional Assays with Anti-DiCo Mix Antibodies
Show Similar Inhibition of Multiple P. falciparum Strains
The functional activity of anti-DiCo mix antibodies from the
four immunisation groups was determined in vitro on a broad panel
of culture-adapted P. falciparum strains (FCR3, NF54, HB3, L32,
7G8 and CAMP). Antibodies were tested at a 2-fold dilution from
6–0.75 mg/ml against all parasite strains.
At the highest concentration tested, antibodies from the seven-
antigen immunisation in CoVaccine HT
TM (Gp 1, n=1,
representing a pool with n=98) showed % growth inhibition of
75.1%, 81.9%, 87.2%, 88.3%, 89.1% and 93.9% against the L32,
HB3, NF54, 7G8, FCR3 and CAMP parasite strains, respectively.
The single sample available for testing in this group however
meant these values could not be directly compared with the mean
% inhibition of the 5 or 8 different rabbit IgGs in the other
immunisation groups. The functional activity of this sample
against three of the six parasite strains (FCR3, HB3, NF54) was
therefore compared with that of IgGs purified from a serum pool
from all 8 rabbits immunised with DiCo mix in CoVaccine HT
TM
(Gp 2) in separate experiments. The % inhibition of pooled
antibodies from the seven-antigen immunisation were the same as
that of the DiCo mix pooled antibodies against NF54 and FCR3
parasite strains, but slightly higher than that of DiCo mix pooled
antibodies against HB3 parasites (Figure 3). Moreover, the %
inhibition of these three parasite strains by the DiCo mix pooled
antibodies compared favourably with the corresponding mean %
inhibition estimated from the measured inhibitions of the
individual rabbit IgGs to DiCo mix in CoVaccine HT
TM
(Figures 3 and 4).
The level of in vitro inhibition was the same for all the three
DiCo mix immunisation groups (Gp 2, Gp 3 and Gp 4) against five
of the six parasite strains, with the L32 strain being the exception
(Figure 4). At the highest concentration tested (6 mg/ml), mean %
growth inhibition of antibodies induced against DiCo mix in
CoVaccine HT
TM (Gp 2, n=8) was between 65 and 82% whilst
that of antibodies against DiCo mix in Montanide ISA 51 (Gp 4,
n=5) was between 65 and 81% against the five strains (Figure 4).
Antibodies against DiCo mix in Montanide IMS (Gp 3, n=8) had
the lowest mean % growth inhibitions (between 37% and 58%)
against all five strains (Figure 4). Although inhibition of the L32
strain was generally lower in all immunisation groups (47.3% for
Table 2. Mean % antibody depletion from FVO and 3D7 AMA1-coated plates.
Capture
antigen Competitor antigen Gp 1 (7Ag/HT) n=9 Gp 2 (3Ag/HT) n=8 Gp 3 (3Ag/IMS) n=8 Gp 4 (3Ag/ISA 51) n=5
3D7 AMA1 FVO 83.9
(81.6–86.2)
85.4
(81.8–89.0)
81.4
(78.1–84.7)
82.8
(79.1–86.5)
HB3 90.5
(89.2–91.8)
89.8
(88.4–91.1)
90.5
(88.0–93.0)
88.1
(85.3–91.0)
CAMP 86.4
(84.1–88.7)
86.5
(81.9–91.2)
85.6
(81.7–89.4)
85.3
(82.6–88.0)
3D7 96.8
(95.7–97.9)
98.1
(96.6–99.6)
98.0
(95.3–100.7)
92.5
(90.3–94.7)
FVO AMA1 FVO 96.1
(95.3–96.8)
97.5
(96.3–98.7)
97.5
(96.4–98.6)
94.3
(93.0–95.6)
HB3 95.0
(93.9–96.0)
95.7
(94.5–96.8)
96.3
(95.5–97.1)
94.1
(92.7–95.6)
CAMP 82.9
(80.6–85.2)
83.6
(80.5–86.6)
78.3
(74.9–81.7)
83.6
(79.5–87.7)
3D7 73.4
(70.5–76.3)
81.8
(79.7–83.9)
75.5
(70.2–80.8)
67.7
(61.8–73.7)
Antibody depletion after competition ELISA, values reported as mean % depletion (95%CI).
7Ag – vaccine containingDiCo mix + four AMA1 alleles from FVO, HB3, 3D7 and CAMP parasite strains.
3Ag – vaccine containing DiCo mix.
NM &DM – competitor antigen mixtures comprising natural AMA1 alleles (FVO, HB3, 3D7, CAMP) and DiCo mix, respectively.
doi:10.1371/journal.pone.0015391.t002
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IgG), the trend across immunisation groups was similar to that for
the other parasite strains. The observed lower inhibition of L32
parasites may be explained by the many polymorphic amino acids
(R197, D207, I224, N244, P330, R395 and T498) within the L32
AMA1 sequence that do not occur in any of the three DiCo
proteins, aside those in the prodomain, and mutations at N-
glycosylation and cleavage sites (Figure 5).
Since the proportions of strain-specific and cross-reactive
antibodies as measured by competition ELISA were constant
across immunisation groups, the lower GIA activity of the
Montanide IMS group may be explained by the lower levels of
the relevant cross-reactive antibodies measured in ELISA. Figure 6
shows that antibody levels against the relevant PfAMA1 alleles
correlate with the extent of in vitro inhibition of parasite strains that
express those alleles. Thus the effect of adjuvant on the
Figure 3. Growth inhibition of Plasmodium parasites by antibody pools from the 3-antigen and 7-antigen immunisation groups. The
7-antigen immunisation group (Gp 1) had only a single sample (antibodies purified from a pool of 98 rabbit sera), hence a direct comparison of the
functional activities of antibodies from the 3 and 7-antigen immunisation groups could not be made. The growth inhibitory activity of IgGs purified
from a pool of all rabbits immunised with DiCo mix (3-antigen, Gp 2) in the same adjuvant (CoVaccine HT
TM) was therefore compared with that of the
single Gp 1 sample against the FCR3, HB3 and NF54 parasite strains. Plots represent the mean % inhibition 6 SEM for replicate measurements for
each sample. Blue filled circles (N) represent the Gp 1 pooled sample and the red filled squares (&) represent the Gp 2 pooled sample.
doi:10.1371/journal.pone.0015391.g003
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cross-strain antibodies and not the quality of antibodies.
Discussion
Antibodies to epitopes that are shared between different
PfAMA1 alleles (cross-reactive/conserved) have been shown to
be relevant for broad strain parasite inhibition in vitro [16,26,27],
and may be potentially important in the field [28]. We have
previously shown that immunisation with mixed PfAMA1 alleles
induces a high proportion of such antibodies [15], and this
represents an important strategy for dealing with allelic polymor-
phism in key antigenic vaccine targets like AMA1. The number of
allelic variants of the antigen that are needed for a universally
functional vaccine however remains a subject of discussion. This
number will be dependent on the underlying mechanism of
antibody production upon immunisation with a mixture of slightly
different immunogens. Our current working hypothesis is that
such a formulation will have strain-specific epitopes diluted out
and this will preferentially enhance the presentation of shared
epitopes to the relevant antibody-producing effector systems in vivo,
thereby increasing the breadth of antibody response. Our
Diversity-Covering approach is premised on this hypothesis, and
in designing the DiCo proteins, polymorphic amino acids of high
frequency (. 10%) in naturally occurring PfAMA1 sequences
have been incorporated two or three times [18]. Thus the DiCo
proteins intrinsically have another level of coverage of polymor-
phism, and are expected to further increase the breadth of
antibody response. This study compared the proportions of cross-
strain antibodies elicited in separate rabbit immunisations with
three and seven antigens, and also assessed the adjuvant effect on
antigen-binding specificity of elicited antibodies.
Data from competition ELISA on plates coated with any one of
five AMA1 antigens (DiCo 1, DiCo 2, DiCo 3, FVO or 3D7)
showed that the binding specificities of antibodies induced in the
seven-antigen immunisation were not distinguishable from those
induced in the three-antigen immunisation (Gps 1 & 2 of Table 1
and Table 2). Thus the addition of four extra antigens to the three
Figure 4. Growth inhibition of Plasmodium parasites by antibodies elicited with the three DiCo mix vaccines. Antibodies from all
immunisation groups were tested on each of six culture-adapted strains (7G8, CAMP, FCR3, HB3, L32 and NF54) of P. falciparum. Plots represent the
mean % inhibition 6 SEM for all antibody samples within an immunisation group. Blue filled circles (N) represent Gp 2 (DiCo mix in CoVaccine HT
TM,
n=8), green open diamonds (e) represent Gp 3 (DiCo mix in Montanide IMS, n=8) and red filled squares (&) represent Gp 4 (DiCo mix in Montanide
ISA 51, n=5).
doi:10.1371/journal.pone.0015391.g004
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the proportion of antibodies against cross-reactive epitopes.
Antibodies induced against a mixture of three PfAMA1 alleles
have been previously shown to exhibit greater cross-reactivity than
antibodies against a single allele [15]. The current data thus
suggests a plateau effect and a practical limit on the number of
alleles that are needed to elicit the broadest antibody response
possible.
Comparison of antibody depletion patterns of the four PfAMA1
competitor antigens (FVO, HB3, 3D7 and CAMP) showed that
the multi-allele vaccines least covered the 3D7 and CAMP AMA1
alleles, while HB3 and FVO AMA1 had reasonably better
coverage (Tables 1 & 2). This was more so when assays were
performed on DiCo 2 –coated (Table 1) or FVO AMA1-coated
(Table 2) plates, and the observation was irrespective of the
number of immunising alleles and the adjuvant used. Thus a
fraction of antibodies elicited by multi-allele vaccine formulations
is strain-specific. Alignment of the amino acid sequences of the
three DiCo proteins alongside those of natural PfAMA1 alleles
(Figure 2) shows that apart from the cleavage site mutation
(position K376R), there are five amino acids at polymorphic
positions within the 3D7 AMA1 sequence (N34, R39, Y175, E197,
P330) that are not present in any of the DiCo proteins, while all
polymorphic amino acids in FVO AMA1 are present in at least
one of the three DiCo proteins. Of the five unique amino acids in
3D7 AMA1, two in the prodomain (N34 and R39) do not have
immunological significance since the PfAMA1 prodomain is not
present on the merozoite at the time of erythrocyte invasion
[29,30]. The glutamic acid residue at the heptamorphic hot-spot
position 197 [31] forms part of a cluster of inhibitory epitope
residues within domain I of the protein [26], and occurs in only
8% of 1294 PfAMA1 sequences available (Remarque, unpublished
data). The two other residues (Y175 and P330) are located in other
clusters that are also deemed important in antigenic escape [26].
Although the seven-antigen vaccine includes 3D7 AMA1, there is
likely an over-representation of antibody epitopes that are not
found within 3D7 AMA1. Lower levels of antibodies will thus be
elicited against the 3D7 AMA1-type epitopes, and this fits our
working hypothesis. CAMP and HB3 AMA1 sequences have two
(K228 and H407) and three (N34, R39 and K121) polymorphic
amino acids, respectively, that are not covered in the DiCo
sequences (Figure 2). Residue K228 is likely to occur within an
important domain I cluster [26], while residue H407 is in domain
II and has not as yet been described as part of an important escape
Figure 5. Alignment of DiCo protein sequences (aa25-545) with those of AMA1 present in GIA malaria parasites. AMA1 protein
sequences of malaria parasites used for in vitro growth inhibition assays were accessed from the GenBank database. The DiCo sequences contain
point mutations at the cleavage (K376R, indicated in orange) and potential N-glycosylation (N162Q, T288V, S373D, N422D, S423K, N499Q) sites
(indicated in red), and differ from parasite AMA1 sequences at these sites. Amino acids at 51 polymorphic sites (within aa25-525) also differ between
sequences.
doi:10.1371/journal.pone.0015391.g005
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acids may therefore be relevant for antigenic escape. Residue
K121 occurs within domain I and has not yet been described as
part of an escape cluster. Residues N34 and R39 occur within the
prodomain and are immunologically not relevant.
Amino acids at positions 175 and 228 are in close proximity to
the conserved tyrosine residue at position 251 within the
hydrophobic trough of AMA1 [32]. This tyrosine residue is
believed to be important for interaction with other invasion-
associated proteins [32]. Residues at positions 330 and 407 cluster
away from the hydrophobic trough and residue 121 occurs on the
more conserved face of the molecule. Some of these polymorphic
residues have been predicted to belong to discontinuous B-cell
epitopes within AMA1 (DiscoTope method, referenced in [33]).
Functional antibody assay data supports the observations made
with competition ELISAs. Antibodies from DiCo mix immunisa-
tion groups (Gp 2, Gp 3 and Gp 4) showed consistent levels of
inhibition of five out of six parasite strains tested, with the L32
strain being an exception (Figure 4). In addition, anti-DiCo mix
antibodies elicited with two of the adjuvants (CoVaccine HT
TM
Figure 6. Relationship between ELISA antibody titre and in vitro parasite growth inhibition. Association of antibody levels with in vitro
antibody functionality for three of the four immunisation groups (Gps 2, 3 and 4) is shown for parasite strains whose AMA1 allelic antigens were
available for antibody measurement. In order to obtain an optimal estimate of the association, growth inhibition data at all four antibody
concentrations tested (6.0, 3.0, 1.5 and 0.75 mg/ml) for each sample were included. Plots are based on a four-parameter logistic function, and each
symbol/colour represents individual rabbits in the same immunisation group.
doi:10.1371/journal.pone.0015391.g006
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of all strains. These data collectively indicate an improved breath
of antibody response compared to antibodies from a single allele or
two-allele immunisation [15,16]. The data shows that strain-
specific antibodies, despite being present as determined by
competition ELISA, did not have any significant functional effects
on parasites in vitro. Since strain-specific anti-AMA1 antibodies are
highly inhibitory against homologous strains [9,13,34], it can be
concluded that the multi-allele vaccines induced only very low
titres of these antibodies, confirming our working hypothesis.
The functional activity of the antibody pool from the seven-
antigen immunisation group compared favourably with a similar
pool made from all eight sera in the DiCo mix CoVaccine HT
TM
immunisation group (Figure 3). Thus the seven-antigen vaccine
does not have significant functional benefits over the three-antigen
DiCo mix vaccine. Though inhibition of one of the parasite strains
tested (HB3) was significantly higher for the seven-antigen
immunisation pooled antibodies compared to the three-antigen
pooled immunisation antibodies, this singular observation may not
have biological significance.
The lower in vitro inhibition of L32 parasites is likely due to the
extent of coverage of polymorphism of the L32 AMA1 sequence
by the DiCo mix vaccine. Apart from mutations at the cleavage
(K376R) and N-glycosylation (N162K, T288V, S373D, N422D,
S423K and N499Q) sites, there are seven polymorphic residues
(R197, D207, I224, N244, P330, R395 and T498) that are not
present in any of the three DiCo proteins (Figure 5). Residues at
positions 197, 207, 224 and 244 have already been identified
within or in proximity of important antigenic escape clusters [26],
and it is imaginable that these, in addition to any functional
epitope(s) that include residues P330, R395 and T498, will
contribute to significant levels of strain-specific antibodies to L32
parasites.
Taken together, the data largely suggests parasite inhibition
through recognition of shared PfAMA1 allele epitopes in these
diverse parasites. These functional epitopes are likely to occur in
AMA1 from many other parasite strains, and antibodies to such
epitopes may play a key role in naturally acquired immunity to
malaria [28]. Though partial, clinical immunity is acquired over
time after repeated exposure to diverse parasite strains [35–38]. We
therefore hypothesize that the antibody component of acquired
immunity in semi-immune adults would be mainly to cross-strain
epitopes, in contrast to the alternative model of a time-dependent
acquisition of a diverse repertoire of strain-specific antibodies after
repeated exposure to different parasite strains [28].
The choice of adjuvant for vaccine formulation has been shown
to influence the quality and specificity of the elicited cellular and
humoral responses [20,39,40]. In this study, adjuvant choice
determined the levels of elicited antibodies and thus the extent of in
vitro parasite inhibition observed (Figures 1 and 4). This however
did not influence antigen specificity as antibodies induced in all
four immunisation groups had near similar specificity profiles
(Tables 1 and 2). This observation may be peculiar to DiCo mix as
a vaccine candidate since the three DiCo proteins were designed
to intrinsically cover polymorphism within natural PfAMA1
sequences, and any specificity effects of the different adjuvants
may have been masked by this property of the vaccine candidate.
High levels of antibody of the right quality are required to counter
parasite growth in both in vitro and in vivo systems [15,41]. Thus the
choice of adjuvant for a DiCo mix vaccine, based on the current
data, may have little or no effect on the induction of the relevant
cross-strain antibodies. This is important for this vaccination
strategy since adjuvant influence on antibody specificity would
introduce another level of complexity in achieving the ultimate
functional cross-strain antibodies.
In summary, we show that the four extra PfAMA1 alleles, when
added to DiCo mix in a seven-antigen formulation, do not
broaden the antigen specificity of elicited antibodies further, and
that the three DiCo antigens may on their own be sufficient to
cover PfAMA1 polymorphism. The DiCo mix vaccine elicits
functional broad-strain antibody responses directed mostly to
shared epitopes. Though up to three relevant polymorphic amino
acids in AMA1 sequences from FCR3, HB3, CAMP, NF54 and
7G8 parasite strains were not covered by the DiCo antigens, the
consistent level of inhibition of these strains by anti-DiCo mix
antibodies suggest that 100% coverage of polymorphic residues
may not be necessarily required for a universal vaccine. The lower
inhibition of L32 parasites, which have as many as seven
potentially important polymorphic residues missing from the
DiCo sequences however imply that the DiCo approach would
need to be constantly reviewed, just as is the case for seasonal
influenza vaccines. This is necessary to account for increases in the
frequency of polymorphic amino acids that were low (,10%) at
the time of DiCo design, and indeed for new polymorphic
positions that are likely to evolve in the field. We finally
demonstrate that different adjuvants elicit anti-DiCo mix antibod-
ies with similar antigen specificities, although the absolute levels of
elicited antibodies differ. This enhances the feasibility of
developing an effective multi-allele AMA1-based vaccine with
reduced formulation complexity and warrants further develop-
ment of multi-allele immunisation strategies. We also highlight a
potentially important role for cross-strain antibodies in naturally
acquired immunity to malaria, and the need for novel adjuvants
with improved antibody potentiation properties and safety for use
in AMA1-based subunit vaccine development.
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